Prakash Masand, M.D., is Founder, Chairman, and CEO of Global Medical Education (GME). Dr. Masand was also Consulting Professor of Psychiatry and Behavioral Sciences at Duke University Medical Center in Durham, NC. He previously served as Director of Therapeutic Area Development, Neurosciences Medicine at the Duke Clinical Research Institute.
His work has been published in peer-reviewed journals including The New England Journal of Medicine, American Journal of Psychiatry, Journal of Clinical Psychiatry, and Journal of Clinical Psychopharmacology. Dr. Masand serves on the editorial boards of the Primary Care Companion to the Journal of Clinical Psychiatry, Annals of Clinical Psychiatry, Current Clinical Pharmacology, and The Open Pharmacology Journal.
We discussed the following topics:
- Definitions of treatment-resistant depression.
- The concept of pseudoresistance in treatment-resistant depression: some considerations to keep in mind before labeling a patient as “treatment-resistant”.
- The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study:
- Its strenghts and weaknesses
- Its implications for clinical practice
- When to switch or augment antidepressants.
- Evidence base for augmentation strategies: second generation antipsychotics, lithium, T3, lisdexamfetamine, modafinil, methylphenidate, folate and CBT.
- How long should augmentation therapy be continued in MDD after remission.
- When to use MAOIs.
You can listen the audio by clicking the play button here:
Or if you prefer you can download the audio file to listen on your mobile device by clicking below:
Global Medical Education for Psychopharmacology Institute readers
Dr. Masand offered our readers a free subscription to Global Medical Education, an online library of nearly 700 medical education videos that answer the most relevant, user-driven questions in psychiatry.
You need to:
- Register for GME, click here to go to the registration page.
- Enter the discount code “Facebook” at the sign up page.
How long should augmentation therapy be continued in MDD after remission?:
- Flint AJ, Meyers BS, Rothschild AJ, Whyte EM, Mulsant BH, Rudorfer MV, et al. Sustaining remission of psychotic depression: rationale, design and methodology of STOP-PD. BMC psychiatry. 2013;13(1):38
Thase – Rush criteria for treatment-resistant depression:
PDF: LAI Antipsychotics
Free PDF Download
- New formulations (Aristada, Invega Trinza)
- Practical dosing tables